Investors seeking broad exposure to the smaller half of the U.S. equity market often weigh the Schwab U.S. Small-Cap ETF (SCHA) against the Schwab U.S. Mid-Cap ETF (SCHM). The two funds do not compete directly in a single category; instead, they occupy adjacent rungs of the capitalization ladder, offering distinct but complementary exposures within the same family of low-cost index products. Comparing them helps clarify the structural trade-off between small-cap growth potential and mid-cap stability. In the current environment of shifting interest rate expectations, sector rotation, and evolving earnings cycles, understanding how these funds differ in holdings, sector concentration, and volatility is essential for sound ETF comparison and relative positioning. From what I see, these details matter when building a balanced allocation.
The Schwab U.S. Small-Cap ETF (SCHA) is a passively managed fund that seeks to track the total return of the Dow Jones U.S. Small-Cap Total Stock Market Index. The portfolio holds approximately 1,700 to 1,750 stocks, making it one of the most broadly diversified small-cap vehicles available. Its net expense ratio is about 0.03%–0.04%, and the fund has been operating since November 2009. Top holdings include BitMine Immersion Technologies (BMNR), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Sanmina (SANM), and Wayfair (W). Because the fund is cap-weighted and extremely diversified, the top ten positions account for only a small single-digit percentage of assets. Sector allocation leans toward financial services, healthcare, technology, and industrials. With a three-year beta above 1.0 and a higher standard deviation, SCHA carries a more aggressive small-cap risk profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Schwab U.S. Mid-Cap ETF (SCHM) is a passively managed fund that seeks to track the total return of the Dow Jones U.S. Mid-Cap Total Stock Market Index. It holds roughly 500 mid-cap stocks and carries a net expense ratio near 0.03%–0.04%, with an inception date of January 2011. The portfolio is more concentrated at the top than SCHA, with the largest ten holdings representing a low double-digit share of assets. Notable positions include SanDisk (SNDK), Ciena (CIEN), Lumentum Holdings (LITE), Coherent (COHR), and Bloom Energy (BE). Industrials and information technology dominate the sector mix, followed by financials, healthcare, and consumer discretionary. SCHM's constituents tend to be more established, profitable companies with stronger balance sheets than typical small-caps, and the fund's beta sits near 1.0, indicating volatility roughly in line with the broader market.
Both funds are heavily influenced by the trajectory of U.S. interest rates, credit conditions, and the health of corporate earnings. Smaller and mid-sized companies generally carry more floating-rate debt and are more sensitive to borrowing costs than large-caps, so the direction of Federal Reserve policy remains a key macro driver. Sector rotation has also shaped relative performance, with cyclical areas such as industrials and technology benefiting from infrastructure investment, onshoring, and demand tied to artificial intelligence and data-center buildouts. At the same time, financials face shifting credit and net-interest-margin dynamics, while healthcare exposure responds to regulatory and pipeline developments. Liquidity, refinancing risk, and valuation dispersion across the capitalization spectrum remain important structural risks for both portfolios.
In recent weeks and months, SCHM has generally exhibited more consistent relative positioning than SCHA, reflecting its lower beta and its tilt toward more established, cash-generating mid-cap businesses. SCHA's higher small-cap sensitivity has translated into stronger upside participation during risk-on rallies but also deeper drawdowns during market pullbacks. The divergence in sector exposure matters as well: SCHM's heavier industrials and technology weighting has aligned it with recent cyclical and infrastructure momentum, while SCHA's broader financials and healthcare mix has contributed to slightly higher relative volatility. For investors evaluating fund performance, SCHM has offered a more moderate volatility profile, whereas SCHA represents a higher-beta expression of small-cap market exposure. One thing that stands out is how these patterns hold up across different market regimes.
In my research process, I regularly rely on Tickeron’s AI-powered tools to cross-check sector exposures, volatility metrics, and relative strength signals between funds like these. The AI Screener, for instance, lets me filter across thousands of securities using customizable criteria such as market cap, technical patterns, and performance data, which adds a useful layer when weighing options such as SCHA and SCHM. This approach helps surface data-driven perspectives on positioning without replacing the core fundamental review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SCHA advanced for three days, in 269 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SCHA's RSI Oscillator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on SCHA as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for SCHA just turned positive on October 21, 2026. Looking at past instances where SCHA's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
SCHA moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 65 cases where SCHA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
SCHA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SCHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows